Vertex Pharmaceuticals Incorporated VRTX announced updates on its two novel investigational candidates, zimislecel (formerly ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), based in Boston, specializes in developing innovative treatments for serious diseases, with a focus on cystic fibrosis and type 1 diabetes (T1D ...

Reserve your spot now. Vertex Pharmaceuticals Inc VRTX announced on Friday updates about its type 1 diabetes (T1D) portfolio. The company said it would not be advancing further in VX-264 clinical ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial. The ...

research-stage immunoprotective approaches - BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several updates on the Company’s type 1 diabetes (T1D ...

Vertex Pharmaceuticals saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The company ...

Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to take a look at where Vertex Pharmaceuticals ... both type 1 and type ...

Vertex Pharmaceuticals Incorporated VRTX announced ... which are being developed in separate studies for the treatment of type 1 diabetes (T1D). Zimislecel is designed for the transplantation ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to take a look at where Vertex Pharmaceuticals ... used to assist manage ...